Search results
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
Benzinga via Yahoo Finance· 2 days agoThursday, Bristol Myers Squibb & Co (NYSE:BMY) posted first-quarter revenues of $11.9 billion,...
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Zacks via Yahoo Finance· 2 days agoBristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus...
Bristol Myers to cut 6% of workforce, trim drug pipeline
BioPharma Dive via Yahoo Finance· 2 days agoTwo-thirds of the savings is expected to come out of Bristol Myers’ spending on research and...
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Zacks via Yahoo Finance· 3 days agoBristol Myers’ revenues in the first quarter of 2024 are likely to have been boosted by the sales...
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 days agoEPS guidance. Let's turn to Slide 5 for some details. I'll start with some highlights on commercial...
Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks· 2 days agoWhile the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Zacks via Yahoo Finance· 5 days agoThe Zacks Consensus Estimate and our estimate for Yervoy sales are pegged at $552 million and $534...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 2 days agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
Bristol Myers cutting $1.5B in costs in less than 2 years, with 2,200 employees impacted in 2024
FierceBiotech· 2 days agoBristol Myers Squibb is the latest large pharma to wield the restructuring ax, with plans to cut $1.5 billion in costs by the end of 2025, including laying off more than 2,000 employees. The ...